Kura Oncology, Inc. (KURA) compared with its closest peers (SPRO, AYTU, RMTI, ENTA, FBIO). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Spero Therapeutics, Aytu BioPharma, Rockwell Medical, Enanta Pharmaceuticals, Fortress Biotech, Assembly Biosciences, Nuvation Bio, Tango Therapeutics, Journey Medical and Lifecore Biomedical share Kura Oncology's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | $70.93M | 9.6 |
| Aytu BioPharma, Inc. (AYTU) | $25.12M | -1.0 |
| Rockwell Medical, Inc. (RMTI) | $315.76M | — |
| Enanta Pharmaceuticals, Inc. (ENTA) | $390.28M | -2.8 |
| Fortress Biotech, Inc. (FBIO) | $95.44M | 0.9 |
| Assembly Biosciences, Inc. (ASMB) | $700.00M | -62.0 |
| Nuvation Bio Inc. (NUVB) | $2.43B | -14.9 |
| Tango Therapeutics, Inc. (TNGX) | $3.46B | -10.2 |
| Journey Medical Corporation (DERM) | $213.21M | -16.4 |
| Lifecore Biomedical, Inc. (LFCR) | $172.61M | -15.2 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
KURA overview · KURA earnings · KURA financials · KURA KPIs · KURA documents · KURA ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.